Test Price
2,800 AED✅ Home Collection Available
TARS2 Gene Combined Oxidative Phosphorylation Deficiency Type 21 Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Key Highlights
- Accuracy: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing, validated against curated variant databases.
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test guidance with a DHA-licensed clinical genetic counsellor to explain results and next steps.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The TARS2 Gene Genetic Test comprehensively analyses the TARS2 gene to detect pathogenic variants causing Combined Oxidative Phosphorylation Deficiency Type 21, a rare mitochondrial disorder. This test is essential for accurate diagnosis, family screening, and guiding metabolic management. It is prescribed when a patient presents with unexplained lactic acidosis, developmental delay, muscle weakness, or multi‑organ involvement suggestive of a mitochondrial cytopathy.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene sequencing with 99.9% analytical sensitivity | Targeted analysis of known variants only |
| Method | Next Generation Sequencing (Illumina platform) | Sanger dideoxy sequencing |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics, I emphasise that a positive TARS2 result must always be interpreted alongside the patient’s clinical presentation and family history. This test provides powerful diagnostic confirmation, but it is not a standalone verdict; every report benefits from multidisciplinary correlation to tailor nutritional and supportive therapies.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License: 9294403
Medication Advisory
Do not discontinue any prescribed medication or supplement without explicit consultation with your managing physician. This genetic test does not replace ongoing clinical care.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients unable to provide informed consent (minors require informed legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Exclusion: Active febrile illness or acute metabolic decompensation; specimen collection should be deferred until clinical stabilisation.
- Red Flag: If the patient exhibits sudden neurological deterioration, severe lactic acidosis, or cardiorespiratory distress, seek immediate emergency care—do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. What is the TARS2 gene test and why is it prescribed?
The TARS2 gene test screens for mutations causing combined oxidative phosphorylation deficiency type 21, a severe mitochondrial disorder. It is prescribed when a patient presents with unexplained lactic acidosis, developmental delay, muscle weakness, or multi‑organ involvement suggestive of a mitochondrial cytopathy. A genetic counselling session and pedigree chart are mandatory before sample collection.
2. How is the sample collected and what do I need to prepare?
A small blood sample (or DNA from a cheek swab/FTA card) is taken via a quick, hospital‑grade home visit. No fasting is required, but please inform the phlebotomist of all medications and supplements. For minors, a legal guardian must be present to sign consent under Federal Decree-Law No. 4 of 2016. The sample is transported in ISO‑certified cold‑chain conditions to our DHA‑licensed facility.
3. How long do results take and what support do I receive afterwards?
Results are typically ready within 3 to 4 weeks, and include a comprehensive clinical interpretation report. You will receive a telephonic post‑ guidance session from a DHA‑licensed genetic counsellor who explains the findings, possible inheritance patterns, and recommended follow‑up with a metabolic specialist or nutritionist. All data is protected under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
- Genetic testing and data privacy governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Minors’ testing requires informed guardian consent, in full alignment with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ISO 9001:2015 Certification: INT/EGQ/2509DA/3139; DHA Facility License: 1143.
Clinical & Logistical Metadata
| Test Name | TARS2 Gene Combined Oxidative Phosphorylation Deficiency Type 21 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Buccal Swab (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina Platform |
| ICD-10-CM Code | E88.49 |
| LOINC Code | 88883-9 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians